Early Detection of Disease Using Wearables
Paul Sakuma/Stanford School of Medicine

Early Detection of Disease Using Wearables

Early detection of disease is crucial for early intervention. Nowhere is this more evident than in the detection of infectious disease.

Thu
4/21/22
 
5:30 pm
 - 
Thu
4/21/22
 
7:00 pm
  
·  
Online (Zoom)
5:30 pm
 - 
7:00 pm
Register Now
Add to Calendar 2022-04-21 17:30 2022-04-21 19:00 America/Los_Angeles Early Detection of Disease Using Wearables Early detection of disease is crucial for early intervention. Nowhere is this more evident than in the detection of infectious disease. Online (Zoom)
Share

Early detection of disease is crucial for early intervention. Nowhere is this more evident than in the detection of infectious disease. We have built a real-time smartwatch-based alerting system for the early detection of aberrant physiological signals associated with early infection onset and other stressors. For example, the system can generate COVID-19 warnings, and serve to measure general health conditions via detection of physiological shifts from personal baselines. The system is scalable to millions of users, offering a real-time personal health-monitoring platform on a global scale.

Mike Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine.

He received his Ph.D. at Caltech and carried out postdoctoral training at Stanford University.

Mike is a leader in the field of functional genomics and multiomics, and one of the major participants of the ENCODE project. His laboratory was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These include the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor (TF) binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks.

Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated (e.g. lncRNAs and TF binding sites), and that a high diversity of transcription factor binding occurs both between and within species.

Mike launched the field of personalized medicine by combining different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of a person. His laboratory also pioneered the use of wearables technologies (smart watches and continuous glucose monitoring) for precision health.

He is a cofounder of many biotechnology companies, including Personalis, SensOmics, Qbio, January, Protos, Oralome, Mirvie and Filtricine.

Share
Similar Events
No events found.